Leading Hidradenitis Suppurativa Treatments in the Market
Leading Hidradenitis Suppurativa Treatments in the Market Currently, some of the top medications for treating hidradenitis suppurativa (HS) include BIMZELX (bimekizumab) by UCB Biopharma, COSENTYX (secukinumab) by Novartis, and HUMIRA (adalimumab) by AbbVie/Eisai. Until 2023, HUMIRA dominated the market, even though its US patent expired in December 2016. AbbVie’s strong patent defense in the US…